PENGARUH MODIFIKASI KRISTAL KALSIUM ATORVASTATIN TERHADAP LAJU DISOLUSI
| dc.contributor.advisor | Tidak ada Data Dosen | |
| dc.contributor.advisor | Tidak ada Data Dosen | |
| dc.contributor.author | A FARISAN PRAMANAPUTRA | |
| dc.date.accessioned | 2024-05-22T07:38:40Z | |
| dc.date.available | 2024-05-22T07:38:40Z | |
| dc.date.issued | 2012-08-03 | |
| dc.description.abstract | Kalsium atorvastatin merupakan salah satu obat anti-kolesterol yang memiliki bentuk kristal yang banyak dan dengan kelarutan yang kurang baik, dengan bioavailabilitas yang hanya mendekati 14%. Penelitian mengenai pengaruh perubahan bentuk Kristal kalsium atorvastatin terhadap profildisolusi bertujuan untuk mengetahui terbentuk atau tidaknya Kristal kalsium atorvastatin bentuk lain setelah proses modifikasi dan mengetahui perbandingan profil disolusi berdasarkan hasil uji disolusi terbanding. Metode penelitian meliputi modifikasi Kristal dengan mengacu kepada jurnal European Patent dengan modifikasi pada suhu pemanasan dan pendinginan, karakterisasi terhadap produk kristal yang terbentuk dengan menggunakan difraksisinar x dan spektrofotometer infra merah, juga uji disolusi terbanding. Metode modifikasi Kristal menghasilkan Kristal baru kalsium atorvastatin bentuk V. Hasil modifikasi Kristal kalsium atorvastatin menunjukkan kristalA adalah kalsium atorvastatin tanpa modifikasi, kristal B dan C adalah kalsium atorvastatin modifikasi dengan pelarut etanol dan metanol. Pada hasil uji disolusi terbanding diperoleh bahwa Kristal B dan C melarut 16% dan 6,3% lebih banyak dari kristal A pada 45 menit pada daparfosfat pH 6,8, kristal B dan C melarut 14,55% dan 23,65% lebih banyak dari kristal A pada 45 menit pada daparasetat pH 4,5 kristal B dan C melarut 4,97% dan 7,545% lebih banyak dari kristal A pada 45 menit pada daparasamklorida pH 1,2 Patient of diabetes mellitus type 2 patient has role of insulin, so that occasionally patient of diabetes mellitus type 2 has condition diabetes and diabetic dyslipidemia. So that needed double therapy of antidiabetic and antidyslipidemia. The extract of nutmeg seed (Myristica fragrans Houtt.) has double action as agonist of Peroxisome Proliferator-Activated Receptors (PPAR), they are PPARαand PPARγ which are have avtion as antidiabetic and antidyslipidemia. This study of tablets of nutmeg seed extract free safrole and myristicin (Myristica fragrans Houtt.) has been tested from pre-clinic test and clinic test of phase 1, the results show that product are safe and understanding for its using in healthy volunteer. This experiment is done about the toxicity in patients with type 2 diabetes mellitus. Tablets of nutmeg seed extract free safrole and myristicin are given orally everyday for 28 days with a dose of 300 mg/day. Measurement the levels of Creatinine, SGOT, SGPT, Hematology (Haemoglobine, Leucosite, Eritrosite, Trombosite, and Hematocrite) done on week-0 (M0) as base-line, week-2 (M2) that is 2 weeks (14 days) from M0, and week-4 (M4) that is 4 weeks (28 days) from M0 . Measurements carried out by using the Roche/Hitachi 917 Modular analyzer (Testing of Creatinine, SGOT, and SGPT) with the equipments and Sysmex XT -2000i (testing of hematology). Experimental data were statistically analyzed by Analyze of Varians (ANOVA) Single Factor method. The results of this study showed there is no overall difference in blood triglyceride levels before and after in using of tablets of nutmeg seed extract (Myristica fragrans Houtt.) free safrole and myristicin with a dose of 300 mg/day for 4 weeks (28 days). This results showed that tablets of nutmeg seed extract are safe in patients with type 2 diabetes mellitus.Keywords: Myristica fragrans Houtt, type 2 diabetes mellitus , toxcicity | |
| dc.identifier.uri | https://repository.unpad.ac.id/handle/kandaga/260110080021 | |
| dc.subject | Disolusi | |
| dc.subject | kristalkalsium atorvastatin | |
| dc.subject | Tidak ada keyword | |
| dc.title | PENGARUH MODIFIKASI KRISTAL KALSIUM ATORVASTATIN TERHADAP LAJU DISOLUSI |
Files
Original bundle
1 - 5 of 10
No Thumbnail Available
- Name:
- S1-2012-260110080021-Cover.pdf
- Size:
- 25.59 KB
- Format:
- Adobe Portable Document Format
No Thumbnail Available
- Name:
- S1-2012-260110080021-Abstrak.pdf
- Size:
- 185.73 KB
- Format:
- Adobe Portable Document Format
No Thumbnail Available
- Name:
- S1-2012-260110080021-DaftarIsi.pdf
- Size:
- 8.52 MB
- Format:
- Adobe Portable Document Format
No Thumbnail Available
- Name:
- S1-2012-260110080021-Bab1.pdf
- Size:
- 132.08 KB
- Format:
- Adobe Portable Document Format
No Thumbnail Available
- Name:
- S1-2012-260110080021-Bab2.pdf
- Size:
- 285.64 KB
- Format:
- Adobe Portable Document Format